$AGRX Announces a Poster Presentation of its SECURE Phase 3 Study

PRINCETON, N.J., March 16, 2017 — Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla^®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15.  The poster, titled “The SECURE Study, a Real-World Trial of a Low-Dose Contraceptive Patch: Addressing the Changing U.S. Population,” will be presented at the Contraceptive Technology Conferences on March 16 – 18, 2017 in  San Francisco, CA and March 29 – April 1, 2017 in Boston, MA.  The first author is Anita Nelson, MD, one of the co-primary investigators for the SECURE trial.

The SECURE study was designed to evaluate the efficacy, safety, and tolerability of Twirla in a representative U.S. population of women seeking birth control.  SECURE was a one-year, multicenter, single-arm, open-label trial in 2032 healthy women aged 18 and over, at 102 experienced investigative sites across the United States.

The Company plans to resubmit its new drug application (“NDA”) for Twirla in the first half of 2017.

The Company has filed the poster presentation on a form 8-K with the U.S. Securities Exchange Commission (“SEC”), which can be accessed either from the Company’s website or the SEC’s website.

About Agile Therapeutics
Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com.

Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements” related to the Company’s clinical trials and regulatory submissions. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions and uncertainties. Any or all of the forward-looking statements may turn out to be wrong, or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Our statements about the results and conduct of our clinical trial could be affected by the potential that there are changes in the data or interpretation of the data by the FDA (for example, the FDA may include additional pregnancies in its calculation of the Pearl Index, which would increase the Pearl Index), whether the results will be deemed satisfactory by the FDA (for example, we describe the results of the SECURE trial as positive, the FDA may disagree with that characterization), and whether additional studies will be required or other issues will arise that will delay resubmission of our NDA or negatively impact acceptance, review and approval of Twirla by the FDA; For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. All forward-looking statements are subject to risks detailed in our filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact:  Mary Coleman 609-683-1880

$LLNW Sets New Online Traffic Delivery Record

Limelight Networks, Inc. (Nasdaq: LLNW), a global leader in digital content delivery, today announced that it delivered record online traffic levels on Tuesday, March 14, 2017, across its global content delivery network (CDN).

Limelight surpassed the previous record for peak traffic, which was set on December 13, 2016, by over 20 percent. Limelight also surpassed its previous record for total sustained traffic delivered over a 24-hour period, set on December 25, 2016, by more than 15 percent. The previous records were driven by seasonal volume from significant one-time events. In contrast, yesterday’s records were driven by Limelight receiving a larger share of pre-planned and routine traffic from several of Limelight’s largest customers.

“We’re delighted that our customers continue to entrust us with a growing share of their traffic,” said Dan Carney, senior vice president of operations at Limelight. “We believe that we are delivering more traffic this year due to the significant performance improvements we’ve gained through software optimization and the continued expansion of our global footprint. Software optimization has allowed us to expand capacity at dramatically lower capex levels. The investments we’ve made in our global network resulted in improved quality for our customers, even in the face of high traffic demand. These quality improvements are evident by the continued reduction in calls to our help desk, even as traffic grows.”

Over the last year, Limelight has expanded its network capacity by over 50 percent, its server capacity by over 70 percent, and introduced new key software capabilities and enhancements to meet growing customer demands. Limelight is also consistently rated as one of the leading providers by Cedexis, a third-party performance testing site.

About Limelight
Limelight Networks, a global leader in digital content delivery, empowers customers to better engage online audiences by enabling them to securely manage and globally deliver digital content, on any device. The company’s award winning Limelight Orchestrate™ platform includes an integrated suite of content delivery technology and services that helps organizations secure digital content, deliver exceptional multi-screen experiences, improve brand awareness, drive revenue, and enhance customer relationships — all while reducing costs. For more information, please visit www.limelight.com, read our blog, follow us on Twitter, Facebook and LinkedIn and be sure to visit Limelight Connect.

fama PR on behalf of Limelight Networks
Ted Weismann, 617-986-5009
limelight@famapr.com
or
Investor Inquiries
ir@llnw.com

$INNL Announces Statement re: Possible Offer

ATHLONE, Ireland, March 16, 2017 — The Board of Innocoll Holdings plc (“Innocoll” or the “Company”) (NASDAQ:INNL) notes anomalous movements in Innocoll’s share price this week and confirms that it is in discussions which may or may not lead to an offer for the entire issued share capital of the Company.

Management has been investigating and continues to investigate strategic options for the Company to maximise shareholder value. There can be no certainty that this will lead to an offer for Innocoll or any of its share capital nor as to the terms on which an offer, if any, might be made. The Company has participated in a Type A meeting with the United States Food and Drug Administration (“FDA”) regarding the re-submission to the FDA for approval of XARACOLL. It expects to receive the minutes of the Type A meeting before the end of March and will make a further announcement at that time.

A further announcement will be made when appropriate.

ENQUIRIES

Innocoll Holdings plc

Jose (Pepe) Carmona, Chief Financial Officer
pcarmona@innocoll.com

Piper Jaffray & Co

Peter Day, Managing Director
Peter.c.day@pjc.com

Peter Lombard, Managing Director
peter.a.lombard@pjc.com

Michael Burton-Williams, Principal
michael.g.burton-williams@pjc.com

Further Information

WF-18749527-8

$MCRB to Initiate New SER-109 Clinical Study

Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced plans to initiate a new SER-109 Phase 2 clinical study (ECOSPOR III) in patients with multiply recurrent Clostridium difficile (C. difficile) infection. The ECOSPOR III study design was finalized following a positive Type B meeting with the U.S. Food and Drug Administration (FDA). In a separate announcement today, Seres reported fourth quarter and full year 2016 financial results and provided an update on multiple ongoing microbiome clinical programs.

Seres plans to initiate a new SER-109 clinical study in approximately 320 patients with multiply recurrent C. difficile infection. Study participants will be randomized 1:1 between SER-109 and placebo. To ensure accurate measurement of C. difficile infection, diagnosis of recurrent C. difficile infection for both study entry and for endpoint analysis will be confirmed by C. difficile cytotoxin assay. Patients in the SER-109 arm will receive a total SER-109 dose, administered over three days, approximately 10-fold higher than the dose used in the prior ECOSPOR study. ECOSPOR III will evaluate patients for 24 weeks and the primary endpoint will compare the C. difficile recurrence rate in subjects who receive SER-109 verses placebo at up to eight weeks after dosing. The FDA has agreed that this new trial may qualify as a pivotal study with achievement of a persuasive clinical effect and addressing FDA requirements, including clinical and statistical factors, an adequately sized safety database, and certain CMC parameters.

“We are pleased to have received highly constructive guidance from the FDA regarding further SER-109 clinical development and we plan to initiate a new clinical study as soon as possible,” said Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres. “Our prior SER-109 studies provided important new biological and clinical data that have advanced our pioneering microbiome therapeutic efforts. Based on our learnings and dialogue with the FDA, we believe that we are now positioned to initiate a robust clinical study that may provide the basis for SER-109 approval. There is an urgent need for improved treatments for C. difficile infection, and we believe SER-109 has great potential to address the underlying cause of the disease and become the first approved microbiome therapeutic in this new field of medicine.”

Conference Call Information

Seres’ management will host a conference call today, March 16, 2017, at 8:00 a.m. ET. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 84302413. To join the live webcast and access slides to accompany the conference call, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com.

About SER-109

SER-109, an oral capsule, is Seres’ lead Ecobiotic^® microbiome therapeutic for the treatment of multiply recurrent C. difficile infection. SER-109 is a biologically sourced consortium of bacterial spores designed to catalyze a shift in a dysbiotic gastrointestinal microbiome to a healthier state.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. The Phase 2 study of Seres’ program SER-109 has been completed in multiply recurrent Clostridium difficile infection. Seres’ second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding SER-109 development plans, the timing, design, and results of the ECOSPOR III study , the potential for ECOSPOR III to provide different results than the previous ECOSPOR study, the impact analysis of prior clinical studies may have on clinical outcomes, the potential for ECOSPOR III to qualify as a Pivotal Study, dysbiosis as an underlying cause of C. difficile and other diseases.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding, which may not be available; our limited operating history; the unpredictable nature of our early stage development efforts for marketable drugs; the unproven approach to therapeutic intervention of our microbiome therapeutics; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; potential delays in enrollment of patients which could affect the receipt of necessary regulatory approvals; potential delays in regulatory approval, which would impact the ability to commercialize our product candidates and affect our ability to generate revenue; any fast track or Breakthrough Therapy designation may not lead to faster development, regulatory approval or marketing approval; our possible inability to receive orphan drug designation should we choose to seek it; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; our lack of experience in manufacturing our product candidates; the potential failure of our product candidates to be accepted on the market by the medical community; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; potential competition from biosimilars; failure to obtain marketing approval internationally; post-marketing restrictions or withdrawal from the market; anti-kickback, fraud, abuse, and other healthcare laws and regulations exposing us to potential criminal sanctions; recently enacted or future legislation; compliance with environmental, health, and safety laws and regulations; protection of our proprietary technology; protection of the confidentiality of our trade secrets; changes in United States patent law; potential lawsuits for infringement of third-party intellectual property; our patents being found invalid or unenforceable; compliance with patent regulations; claims challenging the inventorship or ownership of our patents and other intellectual property; claims asserting that we or our employees misappropriated a third-party’s intellectual property or otherwise claiming ownership of what we regard as our intellectual property; adequate protection of our trademarks; ability to attract and retain key executives; managing our growth could result in difficulties; risks associated with international operations; potential system failures; the price of our common stock may fluctuate substantially; our executive officers, directors, and principal stockholders have the ability to control all matters submitted to the stockholders; a significant portion of our total outstanding shares are eligible to be sold into the market; unfavorable or lacking analyst research or reports; and we are currently subject to securities class action litigation. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 10, 2016 and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Seres Therapeutics, Inc.
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com

$EXPI Reaches 3,000 Agent Milestone

Cloud-Based Brokerage Now Among Top Residential Firms in the U.S.

$KOOL Promising Data for the Treatment of Chronic Non-Healing Ulcers

Significant reduction in wound size observed in all treated patients using autologous platelet rich plasma

RANCHO CORDOVA, Calif., March 15, 2017 — Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced encouraging data from a study evaluating the use of autologous platelet rich plasma (PRP) for the treatment of chronic non-healing ulcers.

Results from the 24 patient study entitled “Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series” were published in the peer-reviewed, Journal of Biomedical Science. The study was led by researchers from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis Memorial Research Institute.

In the study, 24 patients with one wound/ulcer of varying etiology were treated with a single dose of PRP injections around the wound alongside a topical administration of autologous platelet gel. The process was completed at the patient’s bedside in a single session within 30 minutes. Healing of the wound/ulcer was observed in patients as early as 4 weeks after the PRP treatment with a mean healing time of 8.2 weeks ±1.9. All patients demonstrated healing of the wound/ulcer, with 17 (70.8%) patients showing a 90% reduction in wound size and 3 (12.5%) patients showing an 80-90% reduction over the course of the 24 week follow-up. The study also reported that there were no adverse events on the day of treatment or during the patient’s 24 week follow-up, demonstrating a good safety profile for the treatment of chronic non-healing wounds/ulcers.

Dr. Venkatesh Ponemone, Study Director and Executive Director of TotipotentRX commented, “We are very pleased with the data from the study and believe that the use of PRP is a major breakthrough for the treatment of chronic non-healing wounds and ulcers. Using Cesca’s point-of-care platform, we are able to develop rapid cell based therapies at the patient’s bedside within 30 minutes significantly reducing the risk and costs associated with current standard of care treatments.”

“This peer-reviewed publication further validates our novel point-of-care platform for rapid cellular based therapies,” commented Dr. Chris Xu, Cesca’s Interim Chief Executive Officer. “As we continue to strengthen our team and evaluate Cesca’s clinical pipeline, these additional data points serve as useful litmus tests to determine the most valuable growth opportunities for the company.”

Chronic non-healing ulcers pose a significant health risk worldwide affecting an estimated 2-6 million people in the United States alone, and are a major cause of non-traumatic lower limb amputations. Despite a variety of standard of care treatments, many chronic ulcers fail to heal or persist for months/years and/or recur after healing, requiring additional advanced wound care therapies. Platelet Rich Plasma, however, has been a major breakthrough in the arena of vascular therapies allowing the use of a patient’s own body cells for wound/ulcer treatment, providing the necessary growth factors that enhance tissue healing.

About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:

• The SurgWerks™ System (in development) — a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.
• The CellWerks™ System (in development) — a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.
• The AutoXpress® System (AXP^®) — a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.
• The MarrowXpress™ System (MXP™) — a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.
• The BioArchive® System — an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.
• Manual bag sets for use in the processing and cryogenic storage of cord blood.

Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics’ forward-looking statements is set forth under the caption “Risk Factors” in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

Company Contact: Cesca Therapeutics Inc. 
ir@cescatherapeutics.com

Investor Contact: The Ruth Group 
Lee Roth / Tram Bui 
646-536-7012 / 7035 
lroth@theruthgroup.com / tbui@theruthgroup.com

$JAKK Announces Sale of $19.3 Million of Common Stock to Joint Venture Partner

JAKKS Pacific, Inc. (NASDAQ: JAKK) today announced that the Company has entered into an agreement with Hong Kong Meisheng Culture Company Ltd. (“Meisheng”) to sell 3,660,891 million shares of the Company’s common stock to Meisheng for a total purchase price of $19.3 million. The transaction is subject to approval by the shareholders of Meisheng’s parent company (Meisheng Culture & Creative Corp., Ltd.), and regulatory filings in China by Meisheng.

Stephen Berman, JAKKS Chairman and Chief Executive Officer, stated: “As a manufacturer of kids’ consumer products and toys, as well as a producer of animated content, we appreciate the significant and broad possible new opportunities the Chinese market represents. We are pleased that Meisheng has made the investment decision to acquire an equity stake in JAKKS. This should fortify our existing relationship as joint venture partners in two jointly owned companies – one that distributes JAKKS products in China and the other that develops new animation content owned by JAKKS and Meisheng. We expect the expanded relationship with Meisheng will put us in an advantageous position to realize greater opportunities in China.

“We are also pleased to announce that upon closing of Meisheng’s share purchase, Xiaoqiang Zhao, Executive Director of Hong Kong Meisheng Culture Company Ltd. and Chairman of the Board of its parent company Meisheng Culture & Creative Corp., Ltd., will join us as a member of JAKKS Board of Directors. He will bring his experience and unique insights to the Board including serving as Chair of a specially created committee aimed at commercial development in the Greater China region, and will be instrumental in helping us gain greater access to the Chinese toy market.”

Xiaoqiang Zhao stated: “Meisheng Culture is one of the leading companies in China’s IP industry through its own IP generation and partnerships with other companies. We have been creating an IP operation and transformational platform consisting of consumer products, games and media, which centers on IP derivatives. We believe we have unique advantages in the global IP industry, from creating, designing, manufacturing to distribution and retail as well as other current and future platforms. Investing in JAKKS is an important factor in our global market strategy. We believe this investment will contribute to Meisheng’s growth and impact in overseas markets. We are optimistic that we will be able to help JAKKS expand its market share in Asia, and especially in China. I have had a long-term relationship with Stephen Berman and a great relationship with JAKKS for more than a decade. Asia is an attractive market with lots of consumers with strong buying power. Together with JAKKS, we look forward to bringing a better experience to consumers in Asia.

“I am honored to be elected as a new member of JAKKS’ Board of Directors. I look forward to bringing my decades of experience in consumer goods to the Board and to further support JAKKS’ growth along with the other members of the Board.”

Meisheng announced in February 2017 that it acquired 1,387,647 shares of the Company’s common stock in open market transactions. In addition to the joint venture companies established by Meisheng and JAKKS, Meisheng Culture & Creative Corp., Ltd. has for many years been a manufacturer for the Company.

About JAKKS Pacific, Inc.

JAKKS Pacific, Inc. (NASDAQ: JAKK) is a leading designer, manufacturer and marketer of toys and consumer products sold throughout the world, with its headquarters in Santa Monica, California. JAKKS Pacific’s popular proprietary brands include BIG-FIGS™, XPV®, Max Tow™ and Friends, Disguise®, Moose Mountain®, Funnoodle®, Maui®, Kids Only!®; a wide range of entertainment-inspired products featuring premier licensed properties; and C’est Moi™, a skincare and performance make-up brand. Through JAKKS Cares, the company’s commitment to philanthropy, JAKKS is helping to make a positive impact on the lives of children. Visit us at www.jakks.com and follow us on Instagram (@jakkstoys), Twitter (@jakkstoys) and Facebook (JAKKS Pacific).

© 2017 JAKKS Pacific, Inc. All rights reserved.

Forward Looking Statements

This press release may contain “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) that are based on current expectations, estimates and projections about JAKKS Pacific’s business based partly on assumptions made by its management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such statements due to numerous factors, including, but not limited to, those described above, changes in demand for JAKKS’ products, product mix, the timing of customer orders and deliveries, the impact of competitive products and pricing, and difficulties with integrating acquired businesses. The “forward-looking statements” contained herein speak only as of the date on which they are made, and JAKKS undertakes no obligation to update any of them to reflect events or circumstances after the date of this release.

$SGOC Signed a letter of intent with Hong Kong Aircraft Engineering Company Limited

HONG KONG, March 15, 2017 — SGOCO Group, Ltd. (Nasdaq: SGOC) (“SGOCO” or the “Company”), a company focused on product design, distribution, and brand development in the display and computer product market in China as well as energy saving products and services worldwide, today announced that BOCA International Limited (“BOCA”), a wholly owned subsidiary of the Company, has signed a letter of intent (the “LOI”) with Hong Kong Aircraft Engineering Company Limited (“HAECO”),  a subsidiary of Swire Group. Pursuant to the LOI, HAECO will engage BOCA to design, supply and install a new Ultra-High Efficiency BOCA Hybrid Power Chiller Plant (the “Project”) through a Performance Contract for HAECO’s facility at the Hong Kong International Airport

Established in Hong Kong in 1950, HAECO is one of the world’s leading independent aircraft engineering and maintenance groups. It is one of the world largest Maintenance, Repair and Overhaul (MRO) service providers in terms of capacity.

Dr. Richard Chan, the Chief Technology Officer of BOCA estimated that the annual electricity running cost saving through the Project is approximately HK$5.4~7.2million (30~40% of the existing chiller plant annual electricity consumption), and also the power consumption will be reduced approximate 5,400,000kWh annually, which equal to reduction of CARON EMISSION 4,212,000kg.

BOCA has successfully installed and operated BocaPCM-TES for a number of real estate projects worldwide, including in the United Kingdom, Italy, Australia, Malaysia and Hong Kong. Regarding this new project of BOCA which the Company acquired at the end of last year, Mr. Shi-Bin Xie, Chief Executive Officer of SGOCO, commented, “We are pleased to see the initial results of the integration of Boca and transformation of the Company to the energy saving and environmental protection business. The Company will continue its efforts to further develop such new business and achieve our goals.”

About SGOCO Group, Ltd.

SGOCO Group, Ltd. is focused on product design, brand development and distribution in the Chinese display and computer product market as well as energy saving products and services. SGOCO sells its products and services in the Chinese market and abroad. For more information about SGOCO, please visit our investor relations website: http://www.sgocogroup.com

For investor and media inquiries, please contact:
SGOCO Group, Ltd.
Tony Zhong
Vice President of Finance
Tel: +852 3610 7777
Email: ir@sgoco.com

Safe Harbor and Informational Statement

This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Forward-looking statements in this release include, without limitation, the effectiveness of the Company’s multiple-brand, multiple channel strategy and the transitioning of its product development and sales focus and to a “light-asset” model, Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to have effective internal control over financial reporting; our success in designing and distributing products under brands licensed from others; management of sales trend and client mix; possibility of securing loans and other financing without efficient fixed assets as collaterals; changes in government policy in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in SGOCO’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. All information provided in this press release and in the attachments is as of the date of the issuance, and SGOCO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

$MVIS Receives First Order for Small Form Factor Display Engine for $6.7 Million

MicroVision, Inc. (NASDAQ: MVIS), a leader in innovative ultra-miniature projection display and sensing technology, today announced that it has received a $6.7 million order for its small form factor display engine (model PSE-0403-103) from an Asian electronics device manufacturer. The customer plans to embed the MicroVision display engines in smartphones.

The electronics Original Equipment Manufacturer (OEM) plans to launch the smartphone product later this year in China and other markets where it has existing distribution of its products. Currently MicroVision expects to begin shipping engines to the OEM in the second quarter of 2017 with a large majority of the units shipping by the end of 2017. Actual timing of shipments of the PSE-0403-103 to this OEM will be finalized in line with the OEM’s product launch timing. Other details of the product or agreement between MicroVision and the OEM are confidential.

This order demonstrates how the small form factor display engine MicroVision announced in November 2016 is suited to applications where small size and power efficiency are required and where flexible design of the module is needed by the OEM. The electronics OEM that is designing the smartphone with an embedded projector required an electronics board layout that varied from the standard form of MicroVision’s PSE-0403-101 display engine. MicroVision was able to quickly design a form factor that met the requirements of the OEM and could be manufactured by MicroVision’s supply chain partner. This module, PSE-0403-103, uses the same MEMS and ASICS¹ components as the standard MicroVision PSE-0403-101 engine with a configuration that supports the design of the OEM’s product.

MicroVision began shipping samples of its small form factor display engine to customers, including this OEM, in December 2016.

¹ Micro-electrical mechanical systems (MEMS) and Application-specific integrated circuits (ASICS)

About MicroVision
MicroVision is the creator of PicoP® scanning technology, an ultra-miniature laser projection and sensing solution based on the laser beam scanning methodology pioneered by the company. MicroVision’s platform approach for this advanced display and sensing solution means that it can be adapted to a wide array of applications and form factors. It is an advanced solution for a rapidly evolving, always-on world. Extensive research has led MicroVision to become an independently recognized leader in the development of intellectual property. MicroVision’s IP portfolio has been recognized by the Patent Board as a top 50 IP portfolio among global industrial companies and has been included in the Ocean Tomo 300 Patent Index. The company is based in Redmond, Wash.

For more information, visit the company’s website at www.microvision.com, on Facebook at www.facebook.com/MicroVisionInc or follow MicroVision on Twitter at @MicroVision.
MicroVision and PicoP are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Forward-Looking Statements
Certain statements contained in this release, including those relating to fulfillment of purchase orders and future product and product applications are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company’s forward-looking statements include the following: our ability to raise additional capital when needed; products incorporating our PicoP® scanning technology may not achieve market acceptance, commercial partners may not perform under agreements as anticipated, we may be unsuccessful in identifying parties interested in paying any amounts or amounts we deem desirable for the purchase or license of IP assets, our or our customers failure to perform under open purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in the company’s SEC reports, including the company’s Annual Report on Form 10-K filed with the SEC. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

MicroVision
Investors:
Dawn Goetter, 425-882-6629
ir@microvision.com
or
Media:
Nicole Cobuzio, 732-212-0823 ext. 102
nicolec@lotus823.com

$CPRX Announces Positive Data from Investigator-Sponsored Trial of Firdapse®

• Catalyst intends to proceed to U.S. multi-center pivotal trial
• Expects additional data to be presented at upcoming medical congresses in 2017

CORAL GABLES, Fla., March 15, 2017 — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare neuromuscular and neurological diseases, today announced positive top-line results from the investigator-sponsored trial evaluating Firdapse® (Amifampridine Phosphate) as a treatment for myasthenia gravis patients with anti-MuSK antibodies (MuSK-MG). MuSK-MG, is an ultra-rare sub-population of myasthenia Gravis (MG) patients which is a debilitating neuromuscular disease, and there are currently no FDA approved therapies for this specific form of MG.  Both of the co-primary efficacy endpoints of change from baseline (CFB) in total Quantitative Myasthenia Gravis (QMG) score (p=0.0003) and CFB in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score (p=0.0006) were statistically and clinically significant in this seven patient trial.  Several secondary efficacy measures also achieved statistical significance.  Amifampridine phosphate was well tolerated in this population of patients.

The study was conducted by a team of researchers led by Renato Mantegazza, MD, Director, Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico Carlo Besta in Milan, Italy, a major referral center for MuSK-MG patients.  The study was designed as a randomized (1:1), double-blind, placebo-controlled, crossover, outpatient study to evaluate the safety, tolerability and potential efficacy of amifampridine phosphate in patients diagnosed with MuSK-MG.  Catalyst provided funding, study drug, and placebo for this trial.

Dr. Mantegazza, the principal investigator of this trial, stated, “Our prospective study evaluating amifampridine phosphate for the symptomatic relief of antibody positive MuSK-MG was statistically significant in demonstrating that it can be an important treatment option.  Not only are the results statistically significant, but more importantly, there was a large clinical benefit to the patients.  Current treatments for MuSK-MG patients are often inadequate and these patients often face a lifetime of severe complications, including difficulty walking, talking, swallowing, and breathing normally, and in some cases their disease may be life-threatening and require hospitalization and intensive care.  Amifampridine phosphate may offer us an effective treatment option.  I look forward to the day when I can use this drug in routine clinical practice of treating MuSK-MG patients.”

Dr. Silvia Bonanno, one of the investigators from the Istituto Neurologico Carlo Besta, is planning to present these results at the 13th International Conference on Myasthenia Gravis and Related Disorders in May, 2017 in New York City, provided her abstract is accepted as a Hot Topic Short Talk.  This conference is organized by the Myasthenia Gravis Foundation of America and the New York Academy of Sciences.

“These data announced today should allow us to accelerate our MuSK-MG program over the coming months, as we expect to consult with our external experts and regulatory agencies on a pivotal clinical development plan,” said Patrick J. McEnany, Catalyst’s Chief Executive Officer. “I would like to thank Dr. Mantegazza, his associates at Carlo Besta Neurological Institute, and the patients that participated in this important clinical trial.”

“While several effective treatment options exist for the anti-acetylcholine receptor form of myasthenia gravis (AcHR-MG), MuSK-MG has been particularly refractory to current MG treatment options and represents an unmet medical need in the MG community of patients,” stated Gary Ingenito MD, Ph.D., Catalyst’s Chief Medical Officer.  Dr. Ingenito continued: “If the significant clinical effect observed in this trial is reproduced in a multicenter trial, amifampridine phosphate would, upon approval, likely become the first line standard of care for MuSK-MG.  Based on these results we intend to discuss with FDA conducting a registration trial in the United States evaluating amifampridine phosphate for the symptomatic treatment of patients with MuSK-MG.”

About the Clinical Trial

The MuSK-MG “proof-of-concept” trial was a randomized, double blind, placebo-controlled, single site, outpatient, investigator-sponsored, clinical trial to evaluate the safety and efficacy of amifampridine phosphate in myasthenia gravis patients with a positive serological test for the anti-MuSK antibodies (MuSK-MG).  Catalyst provided the investigational drug, placebo, and funding for this clinical trial.

Patients were enrolled into the trial and were titrated to an effective dose of amifampridine phosphate for a period of at least 4 weeks in a “run-in” phase of the trial.  Following achievement of a dosage that effectively managed the patient’s symptoms, the patients were randomized 1:1 into one of two crossover treatment groups.  There were three treatment periods in this crossover design, referred to as a “switch-back” crossover design, that enables both the determination of the effect of the treatment as well as the correction of any “subjective carryover” from earlier treatment periods into later treatment periods.  Carryover in crossover designs is a common concern of regulatory agencies, and this design effectively corrects for and eliminates the effects of carryover from the efficacy assessments.  Each treatment period lasted 1 week for a total of treatment duration of 3 weeks alternating with either amifampridine phosphate or placebo.  The co-primary efficacy endpoints of change from base (CFB) in total Quantitative Myasthenia Gravis (QMG) score and CFB in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score at the 7th day of each period were assessed using a mixed carryover effects statistical model of Kunert and Stufken.  Secondary endpoints consisted of, in order, CFB in Myasthenia Gravis Composite (MGC) Score, CFB in Neurological Institute Carlo Besta-Myasthenia Gravis (NICB-MG) score, proportion of patients with a 2, or larger, point reduction in MG-ADL, proportion of patients with a 3, or larger, reduction in MGC, CFB in Myasthenia Gravis Quality of Life, 15 domain, (MG-QoL 15) score, and CFB in Fatigue Severity scale (FSS).  Catalyst’s funding of this study included the use of a CRO, and this study was run as a well-controlled trial suitable for regulatory submission.

About MuSK Myasthenia Gravis

About 15% of MG patients test negative for the acetylcholine receptor antibody. These patients have seronegative (SN) MG. Approximately 40-50% of these patients with SNMG (equating to an estimate of approximately 4,500 patients in the United States) test positive for the anti-MuSK antibody. MuSK is a protein that is required for the maintenance of the neuromuscular junction and patients with the anti-MuSK antibody are identified as having MuSK-MG. MuSK-MG is a clinically distinguishable, more severe form of MG. The disease is characterized by a predominance in females, a prevalent involvement of cranial and bulbar muscles, high incidence of respiratory crises and a resistance to treatment. Although many patients with MuSK MG are presently treated with anticholinesterase inhibitors or immunosuppressants, such patients do not generally respond adequately to these treatments.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat refractory infantile spasms and possibly refractory Tourette’s Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including whether the receipt of breakthrough therapy designation for Firdapse will expedite the development and review of Firdapse by the FDA or the likelihood that the product will be found to be safe and effective, the timing of Catalyst’s second trial evaluating Firdapse for the treatment of LEMS and whether the trial will be successful, whether Catalyst’s assumptions in its updated business plan will be accurate and the impact of unanticipated events or delays in projected activities on Catalyst’s cash requirements and on Catalyst’s ability to get to an accepted NDA submission for Firdapse without the need for additional funding, what clinical trials and studies will be required before Catalyst can resubmit an NDA for Firdapse for the treatment of CMS and whether any such required clinical trials and studies will be successful, whether any NDA for Firdapse resubmitted to the FDA will ever be accepted for filing,  the timing of any such NDA filing or acceptance, whether, if an NDA for Firdapse is accepted for filing, such NDA will be given a priority review by the FDA, whether any future trial evaluating Firdapse for the treatment of MuSK-MG will be successful and whether Catalyst can obtain the funding required to conduct such trial, whether Firdapse will ever be approved for commercialization, whether Catalyst will be the first company to receive approval for amifampridine (3,4-DAP), giving it 5-year marketing exclusivity for its product, whether CPP-115 will be determined to be safe for humans, what additional testing will be required before CPP-115 is “Phase 2 ready”, whether CPP-115 will be determined to be effective for the treatment of refractory infantile spasms or possibly Tourette’s Disorder, or for any other indications, whether Catalyst can successfully design and complete a bioequivalence study of its version of vigabatrin compared to Sabril that is acceptable to the FDA, whether any such bioequivalence study the design of which is acceptable to the FDA will be successful, whether any ANDA that Catalyst submits for a generic version of Sabril will be accepted for filing, whether any ANDA for Sabril accepted for filing by the FDA will be approved (and the timing of any such approval), whether any of Catalyst’s product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2015 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com

Media Contacts
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 529-2522
pmcenany@catalystpharma.com

$DPW Awarded $50 Million Purchase Order

Largest Order in the Company’s History from Manufacturer of Disruptive Technology

FREMONT, Calif., March 15, 2017 — Digital Power Corporation (NYSE Mkt:DPW) has been awarded a 3-year, $50 million purchase order by MTIX Ltd., headquartered in Huddersfield, West Yorkshire, U.K., to manufacture, install and service textile treatment systems that utilize MTIX’s proprietary Multiplexed Laser Surface Enhancement (MLSE™) system.  MTIX has developed a cost effective and environmentally friendly material synthesis technology featuring a virtual dry process and breakthrough technology for textile applications utilizing the MLSE™ system which uses a combination of high voltage, high frequency electrical discharge plasma and laser energy to imbue textiles with desirable technical characteristics.

“This purchase order represents a significant business step by the Company since the order will enhance our power solution core technology business, as well as open new market opportunities,” stated Mr. Amos Kohn, the Company’s President and Chief Executive Officer.  “Because of our well-established international engineering and manufacturing capabilities, Digital Power Corporation is the perfect partner for MTIX Ltd.  We will leverage our UK based subsidiary, Digital Power Limited, to manufacture, install and service the initial systems in this order for U.K./European based customers.  Our expertise with power solution systems for the commercial and defense markets works well for the design of the MLSE™ system, which has components that include a sophisticated plasma and energy system,” Kohn further stated.  This purchase order also validates the Company’s effort to seek new business opportunities.  Through its strategic investments, the Company has acquired an indirect interest in MTIX and its proprietary technology.

The state-of-the-art MLSE™ technology can be applied to a wide range of textiles and materials and yields economic and environmental benefits.  Integrated with an existing process line or operating as a standalone unit, the MLSE™ system reduces greenhouse gas emissions, water consumption and the use of hazardous and toxic chemicals in the manufacturing process while providing enhancements to final products.

The MLSE™ technology can be employed at all stages of materials processing and surface preparation including cleaning, dyeing, printing and finishing.  MLSE™ is essentially a dry process, carried out at atmospheric pressure and using safe, inert gases with a combination of plasma and photonic energy to effect material synthesis.  The intensity of the hybrid energy and an admixture of various gases determine the nature of the fabric enhancement.

Functional treatments and outcomes that are possible with MLSE™ include:

• Textile surface preparation
• Printing enhancements
• Dyeing process enhancements
• Hydrophobicity, oleophobicity, stain resistance and durability
• Fire retardancy
• Antimicrobial properties

Kohn further stated, “We are proud to partner with MTIX on such a revolutionary technology with so much potential for the textile industry. As part of our strategic alliance with MTIX, we will manufacture and support this unique technology, which offers significant performance improvements, processing cost savings and environmental benefits.”  Mr. Kohn continued, “With the system’s ability to produce superior products while reducing the environmental impact of materials processing in an industry that traditionally uses high levels of water, energy and chemicals, we expect to continue to supply this “green technology” for major international textile manufacturers in the coming years.”

Digital Power Limited, a wholly owned subsidiary of Digital Power Corporation, will manufacture, install and service MLSE™ systems for the UK and European textile market. Its global presence and collaboration with MTIX will allow Digital Power Corporation to offer opportunities for fabric manufacturers and processors to increase their market share and to process products by innovative and efficient means.

About Digital Power Corporation
Headquartered in Fremont, Calif., Digital Power Corporation designs, manufactures and sells high-grade customized and off-the-shelf power system solutions. Its products are used in the most demanding telecom, industrial, medical and military applications where customers demand high density, high efficiency and ruggedized power solutions. Its wholly owned subsidiary, Digital Power Limited branded as Gresham Power Electronics, is based in Salisbury, UK. Corporate website: www.digipwr.com.

About MTIX Ltd.
MTIX, Ltd. is an advanced materials and processing technology company located in Huddersfield, West Yorkshire, UK. The company has developed a novel, cost effective and environmentally friendly material synthesis technology for textile applications.  The MLSE™ technology for textile applications was partly funded by Eco-Innovation Initiative of the European Union. Website: www.mti-x.com.

Forward Looking Statements

The foregoing press release contains “forward looking statements” regarding future events or results within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Such forward looking statements include, but are not limited to, MTIX and its customers being able to order all of the machines subject to the purchase order, being able to reproduce the MTIX process, benefits and enhancements on a production scale, and the Company’s ability to integrate a sophisticated plasma and energy system.  The Company cautions readers that such “forward looking statements” are, in fact, predictions that are subject to risks and uncertainties and that actual events or results may differ materially from those anticipated events or results expressed or implied by such forward-looking statements.  Further, MTIX and its prospective customers related to the purchase order may modify their purchase forecasts for these products that would increase or decrease the Company’s actual revenue versus current revenue forecast for these customers. The Company disclaims any current intention to update its “forward looking statements,” and the estimates and assumptions within them, at any time or for any reason. More information about potential risk factors that could affect the Company’s business and financial results are included in the Company’s most recent filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available on the Company’s website at www.digipwr.com.

Contact: Digital Power Corporation, 48430 Lakeview Boulevard,
 Fremont, California 94538. 1-877-634-0982; 

For Investor Relations inquiries: IR@digipwr.com or call 1-844-233-2645.

$VRAY Q4 FY16 Conference Call and Webcast, March 16

CLEVELAND, March 14, 2017  — ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2016 financial results, which will take place on Thursday, March 16, 2017 after market close.

ViewRay will hold a conference call on Thursday, March 16, 2017 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 68851407. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at www.viewray.com.

After the live webcast, a replay of the webcast will remain available online on the investor relations page of ViewRay’s corporate website, www.viewray.com, for 90 days following the call. In addition, a telephonic replay of the call will be available until March 23, 2017. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 68851407.

About ViewRay

ViewRay®, Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.

ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

$ALSK Enters into New $195 Million Senior Credit Facility

On March 13, 2017, Alaska Communications Systems Holdings, Inc., as Borrower, Alaska Communications Systems Group, Inc., as Parent (collectively “Alaska Communications”) and subsidiaries of Alaska Communications, as guarantors, and ING Capital LLC, as administrative agent, entered into a new senior credit facility, which provides for term loans including a $120 million tranche maturing in 2022 with an interest rate of LIBOR plus 5% and a $60 million tranche maturing in 2023 with an interest rate of LIBOR plus 7%, in addition to a $15 million revolving credit facility with an interest rate of LIBOR plus 5% (collectively, the “2017 Senior Credit Facility”).

Upon the satisfaction of certain standard conditions, on or before March 28, 2017, the 2017 Senior Credit Facility will be funded and Alaska Communications will use the proceeds to repay in full the outstanding borrowings under its 2015 Senior Credit Facilities totaling approximately $87 million, set aside an amount equal to the $94 million outstanding principal balance of its 6.25% Convertible Notes due May 1, 2018 and to pay fees and expenses related to the transaction. Alaska Communications expects to launch a tender offer to repurchase the convertible notes.

Principal payments on the new debt will be due quarterly commencing December 31, 2017. The larger tranche begins amortization at the rate of 1.25% per quarter for approximately two years and stepping up thereafter, while the second tranche begins amortization at the rate of 0.25% per quarter for approximately three years and stepping up thereafter. The facility will be subject to customary covenants, including two key financial covenant ratios. The first is a net leverage coverage ratio not to exceed 3.75 to 1, stepping down over time, as provided in the facility. The second is a fixed charge coverage ratio of not less than 1.05 to 1, as provided in the facility. The facility also includes a $10 million starter basket to repurchase the Parent’s outstanding stock, subject to, among other things, certain excess free cash flow and liquidity requirements. Purchases in excess of $10 million may also be allowed under the facility if, among other things, an additional net leverage test is met. The facility also provides for incremental loans up to an additional $50 million, subject to obtaining applicable lender commitments.

“We are pleased to announce we have closed an agreement extending our senior debt maturities to 2022 and 2023, and, subject to certain limitations, providing for the repurchase of the convertible notes. The cost of borrowing under the 2017 Senior Credit Facility is similar to that of our 2015 Senior Credit Facilities, which was scheduled to mature next year. We look forward to working with this group of lenders who can support our business over the long term,” Alaska Communications SVP of Finance Laurie Butcher said.

Parent will file a Current Report on Form 8-K that describes the transactions in greater detail. Management is also hosting a conference call and live webcast on Tuesday, March 14, 2017 at 5:00 p.m. Eastern Time to discuss the 4^th Quarter and year-end 2016 earnings results. The live webcast will include a slide presentation. Parties in the United States and Canada can access the call at 1-800-245-1683 and enter pass code 264066. All other parties can access the call at 1-719-325-2120.

Forward-Looking Statements

This press release includes certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs as well as on a number of assumptions concerning future events made using information currently available to management. Readers are cautioned not to put undue reliance on such forward-looking statements, which are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside Alaska Communications’ control. Such factors include, without limitation, Federal and Alaska Universal Service Fund changes, our ability to meet the terms and conditions of the new credit facility, draw down funds under the facility and continue to meet its requirements, our ability to commence and complete the expected tender offer for our 6.25% Convertible Notes or otherwise repurchase such notes due 2018 or make repurchases of shares of Common Stock under the Parent’s repurchase plan or otherwise, adverse economic conditions, the effects of competition in our markets, our relatively small size compared with our competitors, Alaska Communications’ ability to compete, manage, integrate, market, maintain, and attract sufficient customers for its products and services, adverse changes in labor matters, including workforce levels, our ability to service our debt (including pursuant to our refinanced credit arrangements) and refinance as required, labor negotiations, including renegotiating our collective bargaining agreement, employee benefit costs, our ability to control other operating costs, disruption of our suppliers’ provisioning of critical products or services, the impact of natural or man-made disasters, changes in Alaska Communications’ relationships with large customers, unforeseen changes in public policies, regulatory changes, changes in technology and standards, our internal control over financial reporting, and changes in accounting standards or policies, which could affect reported financial results. For further information regarding risks and uncertainties associated with the Parent’s business, please refer to Parent’s SEC filings, including, but not limited to, the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. Copies of Parent’s SEC filings may be obtained by contacting its investor relations department at (907) 564-7556 or by visiting its investor relations website at www.alsk.com or at the SEC’s website, www.sec.gov.

Important Information Regarding the Expected Tender Offer

This press release is for informational purposes only and is neither an offer to buy nor the solicitation of an offer to sell any and all of Alaska Communications Systems Group Inc.’s outstanding 6.25% Convertible Notes due 2018. The expected tender offer described in this press release has not yet commenced, and there can be no assurances that Parent will commence the tender offer on the terms and conditions described in this press release or at all. If Parent commences the tender offer, the tender offer will be made solely by an Offer to Purchase, the Letter of Transmittal and related materials, as they may be amended or supplemented. Stockholders should read Parent’s commencement tender offer statement on Schedule TO expected to be filed with the SEC in connection with the tender offer, which will include as exhibits the Offer to Purchase, the Letter of Transmittal and related materials, as well as any amendments or supplements to the Schedule TO when they become available, because they will contain important information. If Parent commences the tender offer, each of these documents will be filed with the SEC, and, when available, stockholders may obtain them for free from the SEC at its website (www.sec.gov) or from the Parent’s information agent in connection with the tender offer.

About Alaska Communications

Alaska Communications (NASDAQ: ALSK) is a leading provider of advanced broadband and managed IT services for businesses and consumers in Alaska. The company operates a highly reliable, advanced statewide data and voice network with the latest technology and the most diverse undersea fiber optic system connecting Alaska to the contiguous U.S. For more information, visit http://www.alaskacommunications.com or http://www.alsk.com.

$TCON $21 Million Common Stock Purchase Agreement with Aspire Capital

SAN DIEGO, March 14, 2017 — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age‐related macular degeneration and fibrotic diseases, announced today that it has entered into a Common Stock Purchase Agreement of up to $21.0 million with Aspire Capital Fund, LLC (“Aspire Capital”). Under the terms of the Agreement, Aspire Capital has made an initial purchase of $1.0 million of TRACON common stock at $4.50 per share. In addition, Aspire Capital has committed to purchase up to $20.0 million of additional shares of the Company’s common stock at TRACON’s request from time to time during a 30 month period beginning on the effective date of a registration statement related to the transaction and at prices based on the market price at the time of each sale. There are no warrants, derivatives, or other share classes associated with this agreement. Proceeds from the Agreement will be used to further advance the Company’s drug development pipeline and for general corporate purposes.

“This transaction with Aspire Capital provides TRACON with efficient and opportunistic access to capital as we continue to advance through our important clinical milestones,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “We welcome the additional flexibility this agreement brings us as we progress our pivotal study of TRC105 in patients with angiosarcoma, approach the initiation of the first-in-human clinical trial of TRC253 in patients with prostate cancer, and provide updates on our Phase 2 TRAXAR trial of TRC105 in combination with Inlyta® (axitinib) in patients with renal cell carcinoma as well as the Phase 2 AVANTE study of DE-122 and Lucentis® (ranibizumab) in patients with wet AMD through our partnership with Santen.”

“We are excited to make this investment in TRACON and are looking forward to providing the Company with additional financial support throughout the term of our agreement,” commented Steven G. Martin, Managing Member of Aspire Capital. “Through our diligence, we believe that there is significant potential in TRACON’s individual product candidates and also in TRACON’s efficient and differentiated product development platform.”

Under the terms of the Common Stock Purchase Agreement, TRACON will control the timing and amount of any further sale of shares of common stock to Aspire Capital. Aspire Capital has no right to require any sales by TRACON but is obligated to make purchases according to TRACON’s direction. There are no limitations on the use of proceeds, financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement. TRACON maintains the right to terminate the purchase agreement at any time, at its discretion, without any additional cost or penalty.

As consideration for Aspire Capital’s obligations under the Agreement, TRACON also issued 195,726 shares of common stock to Aspire Capital as a commitment fee. TRACON also entered into a Registration Rights Agreement with Aspire Capital in connection with its entry into the purchase agreement that requires TRACON to file a registration statement regarding the shares sold to Aspire Capital. Additional detail regarding the Common Stock Purchase Agreement and related Registration Rights Agreement is set forth in TRACON’s Current Report on Form 8-K, filed today with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About TRACON

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON’s website at www.traconpharma.com.

About Aspire Capital Fund, LLC

Aspire Capital Fund, LLC is a Chicago-based, long-only investment fund focused on making open market and direct equity investments in publicly traded companies. Aspire Capital Fund, LLC is managed by Aspire Capital Partners, LLC. Aspire Capital invests in a broad range of industries with emphasis in healthcare and technology.

Forward-Looking Statements

Statements made in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding TRACON’s plans to further develop its product candidates, expectations regarding the initiation and timing of future clinical trials by TRACON or third parties, expected development milestones, availability of additional clinical data, potential utility of TRACON’s product candidates and the potential sale of common stock to Aspire Capital and use of proceeds therefrom. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with clinical development; whether TRACON or others will be able to complete or initiate clinical trials on TRACON’s expected timelines, if at all; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; the fact that TRACON has limited control over whether or when third parties complete on-going trials or sponsor additional trials of TRACON’s product candidates; potential changes in regulatory requirements in the United States and foreign countries; TRACON’s reliance on third parties for the development of its product candidates, including the conduct of its clinical trials and manufacture of its product candidates; whether TRACON will be able to obtain additional financing, including whether TRACON will be able to satisfy conditions to sell stock to Aspire Capital; and other risks described in TRACON’s filings with the Securities and Exchange Commission under the heading “Risk Factors”. All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. TRACON undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Company Contact:
Casey Logan
Chief Business Officer
(858) 550‐0780 ext. 236	
clogan@traconpharma.com

Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
Andrew@lifesciadvisors.com

$APVO Expands Bispecific Antibody Portfolio

Preclinical Data on New Anti-CD123 ADAPTIR™ Bispecific Candidates to be Presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting

Source: 
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
JurchisonS@apvo.com

$NDLS Announces Private Placement Financing

BROOMFIELD, Colo., March 14, 2017  — Noodles & Company (the “Company”) (NASDAQ:NDLS) today announced a $31.5 million private placement of Class A common stock to Mill Road Capital II, L.P. (“Mill Road”) on March 13, 2017 (the “Private Placement”), to further strengthen the Company’s balance sheet and fund strategic initiatives.

The Private Placement is expected to satisfy the Company’s previously announced intention to further strengthen its balance sheet following the February 2017 private placement sale of preferred stock and warrants to L Catterton. Accordingly, the Company no longer intends to pursue a public offering of its Class A common stock.

Under the Private Placement, the Company has agreed to issue to Mill Road 8,873,240 shares of Class A common stock at a price per share of $3.55, which is equal to the closing sale price for the Company’s Class A common stock on March 10, 2017. The transaction is expected to close in early April 2017.

Dave Boennighausen, Chief Financial Officer and interim Chief Executive Officer of Noodles & Company, noted, “We are excited to announce this investment by Mill Road Capital, which has a strong record of investments in consumer brands, including in the restaurant industry.” Boennighausen continued, “We are pleased to complete our plans to strengthen our balance sheet, positioning us well to heighten our focus on building the Noodles & Company brand and to make the right strategic investments for the future.”

Thomas Lynch, Mill Road’s Founder, stated, “This significant investment demonstrates our confidence in the management team and the strategic plan the Company has outlined.  We believe Noodles & Company has a bright future ahead of it and look forward to assisting the Company in this transformative year and beyond.”

The proceeds of the Private Placement will be used, in conjunction with proceeds received from the previously announced private placement to L Catterton and cash flow from operations, to satisfy liabilities associated with the Company’s plan to close underperforming restaurants, to satisfy liabilities arising from the data breach that occurred in 2016 and to fund, in part, capital expenditures related to investments in the remaining company-owned restaurants. Jefferies LLC acted as placement agent on the Private Placement.

About Noodles & Company

Noodles & Company is a fast-casual restaurant chain where its globally inspired dishes come together to create a World Kitchen. Recognized previously by Parents magazine as a Top Family Friendly Restaurant and by Health magazine as one of America’s Healthiest Fast Food Restaurants, Noodles & Company is a restaurant where Japanese Pan Noodles rest comfortably next to Penne Rosa and Wisconsin Mac & Cheese, but where world flavors don’t end at just noodles. Inspired by some of the world’s most celebrated flavor combinations, Noodles & Company’s menu offers soups, salads and shareables. Noodles & Company makes everything fresh to order, just as you like it, using quality ingredients. Servers deliver dishes to the table, allowing guests to sit and relax or grab a quick bite.

About Mill Road Capital

Mill Road Capital is a private investment firm focused on investing in and partnering with publicly traded micro-cap companies in the U.S. and Canada. The firm has flexible, long-term capital with the ability to purchase shares in the open market, buy large block positions from existing shareholders, provide capital for growth or acquisition opportunities, or execute going-private transactions. The firm has raised approximately $670 million of aggregate equity capital commitments and has offices in Greenwich, CT and the San Francisco Bay Area. More information can be found at http://www.millroadcapital.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect the Company’s current views with respect to future events and are based on currently available operating, financial and competitive information. Examples of forward-looking statements include all matters that are not historical facts, such as statements regarding costs associated with the Company’s closure of underperforming restaurants, the implementation and results of strategic initiatives, the use of proceeds of the Private Placement and the Company’s future financial performance. The Company’s actual results may differ materially from those anticipated in these forward-looking statements due to reasons including, but not limited to: the Company’s ability to execute its strategies to close underperforming restaurants, reduce restaurant growth and refranchise restaurants in certain of its markets; the Company’s ability to improve the operational and financial performance of its restaurant portfolio; costs associated with the Company’s data security incident, including legal fees, investigative fees, other professional fees and the cost of communications with customers, as well as potential losses associated with settling payment card networks’ expected claims and litigation associated with the data security breach; the Company’s ability to achieve and maintain increases in comparable restaurant sales and to successfully execute its business strategy, including new restaurant initiatives and operational strategies; the success of the Company’s marketing efforts; the Company’s ability to open new restaurants on schedule; current economic conditions; price and availability of commodities; the Company’s ability to adequately staff its restaurants; changes in labor costs; consumer confidence and spending patterns; consumer reaction to public health issues and perceptions of food safety; seasonal factors; weather; and those discussed in the Company’s filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended January 3, 2017. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the statements. Also, the forward-looking statements contained herein represent the Company’s estimates and assumptions only as of the date hereof. Unless required by United States federal securities laws, the Company does not intend to update any of these forward-looking statements to reflect circumstances or events that occur after the statement is made.

Contacts:
Investor Relations
investorrelations@noodles.com

Media
Danielle Moore
press@noodles.com

$EEFT Proposes to Acquire $MGI for $15.20 Per Share

Offer Represents an Approximately 15% Premium Over MoneyGram’s Existing Agreement with Ant Financial and a Premium Of Approximately 28% to the Company’s Closing Price on the Day Prior to the Ant Financial Transaction Announcement

Clearly Superior Offer Provides Significant Benefits to MoneyGram Shareholders Including Certainty to Closing with No CFIUS Requirement and No Closing Condition Related to Receipt of Money Transmitter Licenses

Compelling Strategic Rationale for Future Value Creation, Including Increased Customer Choice Through Complementary Product Offerings

Expected Cost Synergies of Approximately $60 Million in the Second Year Post Close

Meaningful Accretion to Adjusted Earnings Post Close

LEAWOOD, Kan., March 14, 2017 — Euronet Worldwide, Inc. (“Euronet” or the “Company”) (NASDAQ:EEFT), a leading electronics payments provider, today announced that Euronet has made a proposal to acquire all shares outstanding of MoneyGram International, Inc. (“MoneyGram”) (NASDAQ:MGI) for $15.20 in cash for each share of MoneyGram Common Stock and MoneyGram Preferred Stock on an as-converted basis, valuing the company at more than $1 billion, in addition to the assumption of approximately $940 million of MoneyGram’s debt outstanding. The combination of these highly complementary businesses would create a very well-positioned global payments company that would benefit customers and employees in the United States and around the world.

The proposal represents a premium of approximately 15% over the Ant Financial Services Group (“Ant Financial”) offer and a premium of 28% over the closing price of $11.88 for MoneyGram stock on the final day of trading prior to the transaction announcement on January 26, 2017. The offer also represents a premium of approximately 38% to MoneyGram’s volume weighted average share price over the three month period prior to the Ant Financial transaction announcement.  The proposal offers stockholders a clear and significantly more certain path to a faster closing with no required review by the Committee on Foreign Investment in the United States (“CFIUS”) and no closing condition related to securing change of control consents covering money transmitter licenses in the jurisdictions in which MoneyGram operates.

In addition to the compelling value to stockholders, a combination of Euronet and MoneyGram would create substantial benefits for all customers, agents, employees and stakeholders.

• Positioned For Growth – Both companies have highly complementary distribution channels that will best position the combined business to grow in the highly fragmented global money transfer industry that is projected by the World Bank to expand by 4% annually over the next two years.  MoneyGram’s focus on large retailers and national post offices combined with Euronet’s focus on independent agents and its broad set of consumer payment solutions will create a leading value proposition for customers worldwide.  Furthermore, Euronet believes the companies’ combined core strengths will accelerate their respective digital platform growth initiatives.
• Proven & Collaborative Management Team – Euronet’s experienced and disciplined leadership team has long respected the MoneyGram team and is ready to work together to drive incremental growth for the combined business.  Since the acquisition of Ria in 2007, Euronet has grown its money transfer segment from just more than $200 million in pro forma revenue to over $800 million, a CAGR of 16%. Euronet has a proven track record of successfully integrating more than 35 acquisitions and, more significantly, four money transfer businesses, including Ria, IME, HiFX and XE. In addition, over the same time period, Euronet has continued to invest in its money transfer operations, growing employee headcount at a 12% CAGR to support a seven-fold increase in agents while also expanding Pro Forma Adjusted EBITDA margin over 325 basis points.
• Commitment to Compliance – Both Euronet and MoneyGram understand the requirements for robust compliance in the money transfer industry are only increasing as the market continues to expand globally and venture into new digital platforms.  Euronet has an impeccable record of compliance since its founding in 1994 and, together, both companies would give global customers and regulators confidence through a best-in-class compliance program.

Advisors

Wells Fargo Securities, LLC is serving as financial advisor for Euronet, and Gibson, Dunn & Crutcher LLP is acting as legal advisor.

Conference Call Details

Euronet will hold a conference call this morning, Tuesday, March 14, 2017 at 8:00 a.m. Eastern Time to discuss the proposal. Details are below.

The conference call will be accessible via webcast by following the link posted on http://ir.euronetworldwide.com. Participants should go to the website at least five minutes prior to the scheduled start time of the event to register. A slideshow will be included in the webcast. The conference call will also be available by telephone by dialing (877) 303-6313 (USA) or +1- (631) 813-4734 (non-USA).

A webcast replay will be available beginning approximately one hour after the event at http://ir.euronetworldwide.com and will remain available for one year.

The full text of the letter delivered to MoneyGram by Euronet on March 14, 2017 is included below:

March 14, 2017

Pamela H. Patsley
Chairman of the Board of Directors
MoneyGram International, Inc.
2828 North Harwood St.
15th Floor
Dallas, TX 75201

Dear Pamela:

As we have indicated in our discussions with you from time to time, we are convinced that a combination of our two companies presents a highly compelling opportunity for MoneyGram.  Our complementary businesses and cultures would create a very well-positioned global payments company that would benefit customers and employees in the United States and around the world.

With this in mind, and given the high regard we have for MoneyGram’s technology, global network, management team and employees, I am pleased today to submit this proposal on behalf of Euronet Worldwide, Inc.’s (“Euronet”) Board of Directors to acquire all shares outstanding of MoneyGram International, Inc. (“MoneyGram”) for $15.20 in cash for each share of MoneyGram Common Stock and MoneyGram Preferred Stock on an as-converted basis, valuing the equity of the company at more than $1 billion, in addition to the assumption of approximately $940 million in MoneyGram debt outstanding.

We believe our proposal to be substantially superior to MoneyGram’s pending transaction with Ant Financial Services Group (“Ant Financial”) because our offer:

• Delivers significantly more value to MoneyGram stockholders– a premium of approximately 15% over Ant Financial’s offer and a premium of approximately 38% to MoneyGram’s volume weighted average share price over the three-month period ending January 25, 2017, the final day of trading prior to the announcement of the agreement with Ant Financial.
• Presents a faster and a significantly more certain path to closing than the Ant Financial transaction.

Given these factors, which we further describe below, we are eager to open discussions with you as soon as practicable to complete minimal confirmatory due diligence and reach a mutually beneficial agreement that will allow your stockholders to benefit from a more certain path to close and receive maximum value for their shares.

Substantially More Value
Our proposal provides approximately $130 million of additional value above the offer from Ant Financial, representing a premium of approximately 15% over the Ant Financial offer and a premium of 28% over the closing price of $11.88 for MoneyGram stock on the final day of trading prior to the transaction announcement on January 26, 2017. The per share consideration represents a premium of approximately 38% to MoneyGram’s volume weighted average share price over the three-month period prior to the Ant Financial transaction announcement.

Our proposal is not subject to any financing condition. Wells Fargo Bank, N.A. has agreed to provide committed financing for the entire purchase price for the shares and assumption of MoneyGram debt and all associated fees and expenses. Enclosed is a letter from Wells Fargo Bank, N.A., which details their financing commitment.

Certain Path to Closing
Importantly, the combination of our two companies also offers stockholders a clear path to closing, which we view as a significant benefit in comparison to your current agreement with Ant Financial that contains conditions that make closing highly uncertain.  We do not see any comparable uncertainty in our offer.

Unlike your current agreement, our transaction would not require a review by the Committee on Foreign Investment in the United States (“CFIUS”).  The CFIUS approval process is complex and can be lengthy. Already, members of Congress, members of a congressional commission, and others have raised concerns about the transaction with Ant Financial, which include national security risks that CFIUS must carefully evaluate.  MoneyGram’s handling and preservation of personal financial records of millions of U.S. customers for 10 years could complicate CFIUS’s investigation and potential mitigation measures. It appears increasingly clear that many expect the review and investigation of the Ant Financial transaction to be substantial, adding significant uncertainty to its outcome.

State regulators also have an important and wide-reaching role in reviewing these transactions. The change of control process for Ant Financial will be more burdensome and arduous than for Euronet because Euronet already holds money transmitter licenses in all material jurisdictions where MoneyGram operates. We have excellent and longstanding relationships with U.S. state and foreign regulators.  Conversely, new applications from a foreign company without licenses, such as Ant Financial, require substantial time to vet ownership, including ultimate beneficial ownership, and to obtain the necessary change of control consents, often resulting in a long and arduous regulatory review process that may be ultimately unsuccessful. Such failure to obtain regulatory approval would allow Ant Financial to simply walk away from the deal without paying MoneyGram any reverse termination fee.

Our offer does not include comparable conditionality around money transfer permits because we are only requiring that we be given a defined period of time we consider sufficient to obtain all required consents.  This reflects our confidence in our ability to obtain such consents due to our good working relationships with such regulators.

Furthermore, we believe our money transfer segment’s strong, 30-year record and culture of rigorous compliance should give regulators confidence in our ability to manage MoneyGram in a highly compliant manner, including with respect to its obligations under the 2012 Deferred Prosecution Agreement with the Department of Justice and the 2016 Assurance of Voluntary Compliance with 49 States’ Attorneys General.

Finally, we have already had our outside advisors conduct a detailed review and analysis of the proposed transaction, and we are confident in our ability to secure antitrust approval. In that regard, we are willing to stand behind this belief, and have proposed a $69 million antitrust termination fee – which is approximately four times higher than the CFIUS termination fee that Ant Financial offered.

Commitment to Moving Expeditiously
Our proposal is subject to minimal confirmatory due diligence, which will be completed simultaneously with the finalization of the definitive merger agreement. We would anticipate being in a position to execute the agreement within seven days following our receipt of our requested diligence materials.

As you will see from the attached markup of the Ant Financial merger agreement, we are prepared to enter into a merger agreement on terms that are superior to those in the agreement between MoneyGram and Ant Financial.

We are confident that after you have evaluated our proposal, you will agree that its terms are considerably more attractive to your stockholders than the current Ant Financial transaction, that our proposal constitutes a “Company Superior Proposal” under the terms of the Ant Financial merger agreement, and that you will then take the necessary steps to promptly engage in discussions with us regarding our proposal to secure the best offer for MoneyGram stockholders in line with your fiduciary duties.

We understand that after you have provided the appropriate notice to Ant Financial under your agreement, you can authorize management to enter into discussions with Euronet and to provide information to us. We are fully prepared and willing to enter into a confidentiality agreement with you to move this process forward as soon as possible.

We have engaged Wells Fargo Securities, LLC and Gibson, Dunn & Crutcher LLP as our financial and legal advisors, respectively. They are prepared to meet immediately with you and your advisors.

Please note that this offer is non-binding. Execution of a mutually acceptable definitive merger agreement is subject to the approval of our respective boards. We are prepared to move forward expeditiously in conducting limited due diligence, negotiating transaction agreements and working together to obtain all the requisite regulatory approvals required to close the transaction.

Our Board has unanimously approved the submission of this proposal. We encourage MoneyGram to enter into discussions with us promptly so that we can consummate this mutually beneficial transaction in a timely manner. We look forward to hearing from you.

Very Truly Yours,

Michael J. Brown
Chairman and Chief Executive Officer
Euronet Worldwide, Inc.

About Euronet Worldwide, Inc.

Euronet Worldwide is an industry leader in processing secure electronic financial transactions. The Company offers payment and transaction processing solutions to financial institutions, retailers, service providers and individual consumers. These services include comprehensive ATM, POS and card outsourcing services, card issuing and merchant acquiring services, software solutions, cash-based and online-initiated consumer-to-consumer and business-to-business money transfer services, and electronic distribution of prepaid mobile phone time and other prepaid products.

Euronet’s global payment network is extensive – including over 35,000 ATMs, approximately 163,000 EFT POS terminals and a growing portfolio of outsourced debit and credit card services which are under management in 53 countries; card software solutions; a prepaid processing network of approximately 661,000 POS terminals at approximately 305,000 retailer locations in 35 countries; and a global money transfer network of approximately 317,000 locations serving 146 countries. With corporate headquarters in Leawood, Kansas, USA, and 61 worldwide offices, Euronet serves clients in approximately 160 countries. For more information, please visit the Company’s website at www.euronetworldwide.com.

Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP measure that is defined as net income excluding interest, income tax expense, depreciation, amortization, share-based compensation expenses and other non-operating or non-recurring items that are considered expenses or income under U.S. GAAP. Adjusted EBITDA represents a performance measure and is not intended to represent a liquidity measure. Non-GAAP measures may not be comparable to similarly titled non-GAAP measures used by other companies and should be used in addition to, and not a substitute for, measures computed in accordance with U.S. GAAP. See slides 15-17 in our investor presentation included as Exhibit 99.2 to our Form 8-K dated March 14, 2017 for a reconciliation of non-GAAP items to their most directly comparable U.S. GAAP financial measure.

Note on forward-looking statements

This press release contains “forward-looking statements” related to the proposed transaction between Euronet and MoneyGram, including, but not limited to, statements regarding the benefits of the transaction and the timing of the transaction as well as statements regarding the companies’ services and markets. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including the following, among others: MoneyGram and Euronet may not sign a definitive merger agreement on the terms outlined in the document or at all; MoneyGram’s stockholders may not approve the transaction; closing of the transaction may not occur or may be delayed; expected synergies and other financial benefits of the transaction may not be realized; integration of the acquisition post-closing may not occur as anticipated; litigation related to the transaction or limitations or restrictions imposed by regulatory authorities may delay or negatively impact the transaction; unanticipated restructuring costs may be incurred or undisclosed liabilities assumed; attempts to retain key personnel and customers may not succeed; actions by competitors may negatively impact results; and, there may be negative changes in general economic conditions in the regions or the sectors in which Euronet and MoneyGram operate. In addition, please refer to the documents that Euronet and MoneyGram have filed with the SEC on Forms 10-K, 10-Q and 8-K. These filings identify and address other important risks and uncertainties that could cause events and results to differ materially from those contained in the forward-looking statements set forth in this press release. Any forward-looking statements made in this press release speak only as of the date of this press release. Readers are cautioned not to put undue reliance on forward-looking statements, and Euronet assumes no obligation and does not intend to update these forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts

Abernathy MacGregor
Tom Johnson, Patrick Tucker or Cia Williams
(212) 371-5999
tbj@abmac.com
pct@abmac.com
cew@abmac.com

Investor Contacts

Euronet Worldwide
Stephanie Taylor
Director of Financial Planning & IR
(913) 327-4221
staylor@euronetworldwide.com

$VVPR CEO & CFO at the Roth Capital Partners 29th Annual Growth Stock Conference

LONDON, March 13, 2017 — Dr. Philip Comberg, chief executive officer and Carl Weatherley-White, chief financial officer of VivoPower International PLC (“VivoPower”) (NASDAQ:VVPR), are scheduled to present and participate on a panel on Tuesday, March 14, 2017, at the Roth Capital Partners 29^th Annual Growth Stock Conference. The presentation, which will include adjusted earnings expectations, is scheduled to begin at 12:30 p.m. PST. Investors and other interested parties will be able to access a copy of the presentation materials at www.VivoPower.com/shareholders.

About VivoPower

VivoPower is a global next generation solar power company that operates a build, transfer and operate (BTO) model to establish an installed solar power asset base in a capital efficient manner. VivoPower does this by aggregating photovoltaic (PV) solar projects underpinned by long term power purchasing agreements and then arranges corporate and project financing, engineering design and equipment procurement and manages the construction and development of such solar PV projects for asset owners. VivoPower intends to leverage this asset base to sell distributed generation power, and manage and provide power support services (encompassing operations, maintenance and optimization) and data driven energy services for commercial, industrial and government customers, pursuant to long term contracts with the asset owners so as to maximize the performance and value of their solar assets.

Forward-Looking Statements

This communication includes certain statements that may constitute “forward-looking statements” for purposes of the U.S. federal securities laws.  Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions.  The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.  Forward-looking statements may include, for example, statements about the benefits of the transactions described in this communication and plans to make future repurchases of VivoPower’s ordinary shares, including the amount of shares that may be repurchased. These statements are based on VivoPower’s managements’ current expectations or beliefs and are subject to risk, uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive and/or regulatory factors, and other risks and uncertainties affecting the operation of VivoPower’s business. These risks uncertainties and contingencies include business conditions, fluctuations in customer demand, changes in accounting interpretations, management of rapid growth, intensity of competition from other providers of products and services, general economic conditions, geopolitical events and regulatory changes and other factors set forth in VivoPower’s filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. VivoPower is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements whether as a result of new information, future events, changes in assumptions or otherwise.

Contact: 

Carl Weatherley-White
Chief Financial Officer
shareholders@vivopower.com

$ALIM Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain

Brill Pharma S.L. to also serve as agent in price negotiations
with the Spanish Ministry of Health

ATLANTA, March 13, 2017 — Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Alimera Sciences Limited, its European subsidiary based in London, has signed an exclusive agreement with Brill Pharma S. L. (Brill Pharma), Barcelona, Spain, for distribution of ILUVIEN^® in the Kingdom of Spain, Alimera’s sustained release intravitreal injection for the treatment of diabetic macular edema.

Under the terms of this agreement, Brill Pharma will handle promotion, marketing and commercial activities in Spain for ILUVIEN. In addition, Brill will negotiate with the Spanish Ministry of Health on the appropriate confidential net price for reimbursement of ILUVIEN within the Spanish National Health System, as well as on the public price.

“As a continuous microdosing treatment that lasts for up to three years, ILUVIEN can make a major difference to patients with DME in Spain,” said Dan Myers, President and Chief Executive Officer of Alimera. “With the help of Brill Pharma’s experienced team, we expect to reach Spanish patients and their physicians with a truly innovative product that can consistently treat their disease every day and markedly improve their quality of life.”

“Spain has a strong tradition in the use of corticosteroids being one of the largest markets in Europe. The introduction of ILUVIEN will represent a substantial improvement in the long term management of the pathology and the quality of life of a significant number of patients. Brill Pharma will be the first pharmaceutical company with Spanish capital, marketing an innovative intravitreal product in diabetic macular edema,” said Dr. Jordi Martinez Rotllan, Chief Executive Officer of Brill Pharma.

About ILUVIEN

www.ILUVIEN.com.

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant indicated in the E.U. to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant with its continuous microdosing is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months, enabling the physician to treat the disease consistently every day.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.

About Brill Pharma S. L.

Brill Pharma, the Spanish subsidiary of Bristol Laboratories U.K., is based in Barcelona, Spain and was established in September 2012. It markets innovative products in ophthalmology, is already ranked fourth in this specific segment of the Spanish pharma market and was recently recognized as the fastest growing Spanish pharma company in its segment. The company employs more than 60 medical representatives covering Spain. For further details, please visit www.brillpharma.com.

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, that Alimera believes it will reach Spanish patients and physicians with Brill Pharma’s team. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Brill Pharma’s ability to launch ILUVIEN in 2017 in Spain, Brill Pharma’s ability to successfully negotiate a price for ILUVIEN with the Spanish Ministry of Health, Brill Pharma’s ability to provide adequate promotion, marketing and commercial support for ILUVIEN, physician’s in Spain will acceptance ILUVIEN for use with their DME patients, and ILUVIEN acceptance by various institutions in the Spain, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.  In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For press inquiries:
Katie Brazel
for Alimera Sciences 
404-317-8361
kbrazel@bellsouth.net

For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital

$HTBX Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2

Encouraging results evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo^®)

Signs of synergistic efficacy with nivolumab enables expansion to a Phase 2 trial

DURHAM, N.C., March 13, 2017 — Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that the company achieved the efficacy endpoint for its Phase 1b trial evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo^®), for the treatment of non-small cell lung cancer (NSCLC) and that the trial met the expansion criteria to advance into a Phase 2.  In reviewing the Phase 1b data, the Data Monitoring Committee (DMC) determined that the Phase 1b safety endpoint was met and that there do not appear to be additional toxicities seen in the HS-110/nivolumab combination compared to existing data on nivolumab alone.  Furthermore, 5 out of 15 patients treated with the HS-110/nivolumab combination had 20% or greater tumor reduction.  The DMC concluded that the positive safety profile, mechanistic evidence and encouraging signs of synergistic efficacy warranted expansion to a Phase 2 trial.

“We are encouraged by the results from this Phase 1b trial evaluating the therapeutic vaccine, HS-110, combined with the checkpoint inhibitor, nivolumab, in patients with advanced non-small cell lung cancer,” said Daniel Morgensztern, M.D., Associate Professor of Medicine and Director of Thoracic Oncology, Washington University School of Medicine.  “We continue to see that the combination appears to be generally well-tolerated, and the encouraging signs of efficacy warrant a larger sample size.  We’ve seen some patients with increased tumor infiltrating lymphocytes (TIL) after treatment, and anticipate that we can confirm this trend in the Phase 2.”

“We are pleased with the DMC’s decision to expand the trial to a Phase 2 given the positive clinical responses seen to-date.  We saw that those patients with increased levels of TIL at 10 weeks had a durable benefit, with six out of eight of these patients (75%) alive at the one-year follow-up point,” said Jeff Hutchins, Ph.D., Heat’s Chief Scientific Officer and Senior Vice President of Preclinical Development.  “We designed this trial with the Bristol-Myers Squibb Checkmate 057 nivolumab trial in mind, which reported a 19% response rate in a similar patient population. Although this is a small sample size and a non-randomized trial, we believe that this is an encouraging sign that the combination may be more effective than checkpoint therapy alone and could provide therapeutic benefit to a majority of lung cancer patients who do not respond well to checkpoint monotherapy.  We remain focused on enrolling new patients to better characterize the objective response rate, durability of the response and associated immune activity.”

About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response.  Currently, Heat is conducting a Phase 1b trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).

Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.

For more information, please visit www.heatbio.com.

Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events.  In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions.  These statements are based upon current beliefs, expectations and assumptions and include statements regarding the encouraging signs of efficacy warrant a larger sample size, potentially confirming this trend in the Phase 2, the belief that the combination may be more effective than checkpoint therapy alone and could provide therapeutic benefit to a majority of lung cancer patients who do not respond well to checkpoint monotherapy and the potential of Heat’s ImPACT and ComPACT therapies.  These statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements, including the ability of Heat to develop its product candidates and prove them safe and efficacious, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, the company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the company’s  ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, the company’s ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its  ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and its ability to retain its key scientists or management personnel and the other factors described in the company’s annual report on Form 10-K for the year ended December 31, 2015 and other filings with the SEC.  The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Contact:
Jennifer Almond
Investor and Media Relations
919-240-7133
Investorrelations@heatbio.com

$COOL Stockholders Approve Merger

$ETRM vBloc® Neurometabolic Therapy Featured on “The Doctors” TV Show

Segment Featuring vBloc Institute Surgeon Dr. Frank Chae and patient Cindy Hudak Airs March 14

ST. PAUL, Minn., March 13, 2017  — EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that its vBloc^® Neurometabolic Therapy for the treatment of obesity will be featured on the March 14 episode of the Emmy Award-winning syndicated daytime talk show The Doctors. Frank Chae, MD, FACS, Chief Surgeon and Head of the Bariatric Center at Sky Ridge Medical Center in Colorado and Cindy Hudak, one of his patients who received vBloc Therapy will discuss the benefits of vBloc Therapy and Cindy’s personal story of battling obesity. The Doctors, on air since 2008, offers the most timely, topical and practical health, wellness and lifestyle information on daytime television. To find a station where The Doctors airs, please visit http://photos.thedoctorstv.com/when-its-on/

“The Doctors is a well-respected television show many people watch in order to learn about different medical conditions, including obesity, and the latest innovative treatments available to them,” said Dan Gladney, EnteroMedics President, Chief Executive Officer and Chairman of the Board. “We are thrilled The Doctors has decided to feature vBloc Therapy and hope patients who see the segment and are appropriate for its use will take action and contact their doctor to learn more about its benefits. I also want to applaud vBloc patient Cindy Hudak for her great success to date and thank her for sharing her story.”

vBloc Therapy is approved for use in helping with weight loss in people aged 18 years and older who are obese, with a BMI of 40 to 45 kg/m², or a BMI of 35 to 39.9 kg/m² with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea who have had a poor response to trying to lose weight under supervision in the last 5 years.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc^® Neurometabolic Therapy, delivered by a pacemaker-like device called the vBloc^® System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics’ vBloc^® System has received U.S. Food and Drug Administration approval and CE Mark.

Information about the vBloc^® System and vBloc^® Neurometabolic Therapy

You should not have an implanted vBloc^® System if you have cirrhosis of the liver, high blood pressure in the veins of the liver, enlarged veins in your esophagus or a significant hiatal hernia of the stomach; if you need magnetic resonance imaging (MRI); if you have a permanently implanted, electrical medical device; or if you need a diathermy procedure using heat. The most common related adverse events that were experienced during clinical study of the vBloc System included pain, heartburn, nausea, difficulty swallowing, belching, wound redness or irritation, and constipation.

Talk with your doctor about the full risks and benefits of vBloc Therapy and vBloc System. For additional prescribing information, please visit www.enteromedics.com.

If you are interested in learning more about vBloc Neurometabolic Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our vBloc^® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our vBloc^® System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our vBloc^® System; physician adoption of our vBloc^® System and vBloc^® Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission, particularly those factors identified as “risk factors” in the annual report on Form 10-K filed March 8, 2017. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

$AEMD Announces The Conclusion Of Hemopurifier Clinical Study

The Technology is a Candidate to Treat Emerging Bioterror and Pandemic Threats

SAN DIEGO, March 13, 2017 — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the company has concluded an FDA-approved feasibility study designed to assess the safety of the Aethlon Hemopurifier® in health-compromised individuals. The single-site study was conducted at DaVita Med Center Dialysis in Houston, Texas.

The Hemopurifier is a first-in-class medical device that reduces the presence of circulating viruses in infected individuals. The technology is a first-line candidate defense against a broad-spectrum of viruses that are not addressed with antiviral drug therapies, including natural occurring pandemic threats and agents of bioterrorism.  Additionally, the device provides a strategy to augment the benefit of proven antiviral drug regimens.

The Hemopurifier had previously been administered to individuals infected with Hepatitis C virus (HCV), HIV and the Ebola virus, for which it was approved by the FDA under Emergency-Use Authorization.

In the feasibility study, the Hemopurifier was observed to be well tolerated in End-Stage Renal Disease (ESRD) volunteers who were also infected with Hepatitis C virus (HCV). The inclusion of HCV-infected ESRD subjects served as a model to demonstrate virus reduction. No device-related adverse events were observed in enrolled subjects who met the study inclusion/exclusion criteria.

The study originally was estimated to enroll ten subjects, but was concluded after the treatment of eight subjects based on the Hemopurifier being well-tolerated in the study, the breadth of previous human treatment experiences and the absence of qualified HCV-infected ESRD candidates at the study location.

“We achieved our primary study objective, which was to demonstrate that our Hemopurifier can be safely administered to very health-compromised individuals,” stated Jim Joyce, Chairman and CEO of Aethlon Medical. “We will now proceed to submit a final report and look forward to collaborating with our FDA review team to establish market clearance pathways to treat viral threats that are not well addressed with traditional drug therapies.”

In preclinical studies, the Hemopurifier has been demonstrated to capture a wide-range of bioterror and pandemic threats that are not addressed with antiviral drug therapies.

Aethlon believes the device can fulfill the broad-spectrum medical countermeasure objective of the U.S. Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasure Enterprise (PHEMCE).  This initiative is directed toward bioterror, pandemic threats and other pathogens that are not well addressed with drug or vaccine therapies.

The Company also seeks to advance the Hemopurifier under the provisions of the 21st Century Cures Act, which was signed into law in December 2016.  The Act establishes new rules that direct the FDA to approve drugs and devices with greater urgency.  Specific to medical devices, the Act requires the FDA to establish a priority review program for “breakthrough” devices, or for devices that target diseases for which no FDA-cleared or approved alternatives are available.

About The Study Protocol

The study was a single-arm, sequential, controlled feasibility/safety study in which each enrolled subject served as his/her own control. The control period was the week immediately preceding the administration of Hemopurifier therapy, during which eligible subjects were monitored during three standard intermittent hemodialysis sessions, which are require to maintain the life of ESRD patients. Collected data points included vital signs, blood chemistries, hematology and liver function. On weeks two and three, enrolled subjects received the administration of Hemopurifier® therapy three times per week (6-Hemopurifier treatments in total) coincident with their ongoing standard intermittent hemodialysis treatments. During these two weeks, subjects were assessed for the same clinical parameters as during the control period.  The collected data will be included in a final report to be provided to FDA.  The final report will also include observations of viral load reduction during treatment, as well as a quantitative post-treatment assessment of total viruses captured within the Hemopurifier.

About Aethlon Medical, Inc.

Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body’s natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study.  Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients. Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer’s disease (AD) and Chronic Traumatic Encephalopathy (CTE).  ESI’s TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals.  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com. You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company’s ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, including any CTE-related products, that the FDA will not approve the initiation or continuation of the Company’s clinical programs or provide market clearance of the Company’s products, including clearance through  the 21st Century Cures Act, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2016, and in the Company’s other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com

$PRKR Completes Sale of $10 Million Under ATM

JACKSONVILLE, Fla., March 10, 2017 — ParkerVision, Inc. (Nasdaq:PRKR), a developer and marketer of semiconductor technology solutions for wireless applications, today announced that it has completed the sale of approximately 4.1 million shares of its common stock at an average price of $2.46 per share, for aggregate gross proceeds of $10 million, pursuant to an At Market Issuance Sales Agreement (“ATM Agreement”).  The ATM Agreement, which the Company entered into with FBR Capital Markets in December 2016, has now concluded.  In addition to the ATM Agreement proceeds, one of the Company’s newly appointed directors, Mr. Paul Rosenbaum, purchased approximately $170,000 of the Company’s unregistered common stock at market in February.

ParkerVision CEO, Jeffrey Parker commented, “The funds raised from the ATM Agreement provide us with the flexibility and financial pathway to achieve our strategic objectives.  We are well-positioned to successfully launch our new Wi-Fi product line that we believe will have broad appeal to a significant consumer market. Our patented RF energy sampling down conversion technology, which has been broadly deployed in other wireless devices, enables us to offer very competitive products in the residential Wi-Fi market.”

Regarding the Company’s upcoming hearing at the International Trade Commission, Mr. Parker commented, “We look forward to presenting the merits of our infringement case to the ITC next week as we strive to halt the unauthorized use of our patented technologies. While the market has benefited from the adoption of our technology, we continue to seek efficient ways to be fairly compensated for the investments ParkerVision has made and continues to make.”

About ParkerVision

ParkerVision, Inc. designs, develops and markets its proprietary radio-frequency (RF) technologies that enable advanced wireless solutions for current and next generation communications networks. Protected by a highly-regarded, worldwide patent portfolio, the Company’s solutions for wireless transfer of RF waveforms address the needs of a broad range of wirelessly connected devices for high levels of RF performance coupled with best-in-class power consumption.  For more information please visit www.parkervision.com.  (PRKR-G).

Safe Harbor Statement

This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company’s SEC reports, including the Form 10-K for the year ended December 31, 2015 and the Forms 10-Q for the quarters ended March 31, June 30, and September 30, 2016. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.

CONTACT:	
Cindy Poehlman		
Chief Financial Officer	
ParkerVision, Inc.		
904-732-6100		
cpoehlman@parkervision.com

or 

Matt Steinburg
The Piacente Group
212-481-2050
parkervision@tpg-ir.com

$STML to Present at the 29th Annual ROTH Conference

NEW YORK, March 10, 2017  — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 29^th Annual ROTH Conference on Monday, March 13, 2017 at 12:00 PM PT (3:00 PM ET). The conference is being held at The Ritz-Carlton, Orange County. A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.

About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need. A Phase 2 pivotal trial with SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123), is enrolling patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an indication for which SL-401 has been granted Breakthrough Therapy Designation (BTD). Additional Phase 2 trials with SL-401 are enrolling patients with other malignancies including high-risk myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML) in remission with minimal residual disease (MRD). A Phase 1/2 trial with SL-401 in combination with pomalidomide is enrolling patients with relapsed/refractory multiple myeloma. A Phase 1 dose escalation trial is enrolling patients with advanced tumors with SL-801, a novel oral small molecule reversible inhibitor of XPO1. A Phase 2 trial with SL-701, an immunotherapy designed to activate the immune system to attack tumors, is completed and patients with second-line glioblastoma are being followed for survival.

Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation, internal review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities including the risk that the FDA ultimately does not approve any of our product candidates; our plans to develop and commercialize our product candidates; market acceptance of our products; reimbursement available for our products; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com

$SNGX to Present Results from Ricin Toxin Vaccine Program

PRINCETON, N.J., March 10, 2017  — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will present results from its ricin toxin vaccine (RiVax™) development program at the Society of Toxicology 56^th Annual Meeting. The meeting is being held on March 12-16, 2017 in Baltimore, MD and the poster will be available for viewing on Wednesday, March 15 from 9:30 a.m. to 12:45 p.m.

Poster Presentation Details:

• Verification of Lethal Doses of Inhaled Ricin in Rhesus Macaques to Support Vaccine Development presented by Dr. Gensheng Wang, Lovelace Respiratory Research Institute and Dr. Thomas Measey, Soligenix Inc.

RiVax™ is the Company’s proprietary vaccine candidate for the prevention of exposure to ricin toxin that utilizes a unique antigen that is completely devoid of the toxic activity of ricin. When formulated with Soligenix’s proprietary vaccine heat stabilization technology, ThermoVax^®, RiVax™ has demonstrated significantly enhanced thermostability and 100% protection in preclinical ricin aerosol challenge models.

The poster presentation focuses on the further optimization of the primate ricin challenge model that is important to facilitating future approval of RiVax™ under the US Food and Drug Administration (FDA) “Animal Rule”. This work was funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health, via Contract #HHSN272201400039C.

With the recent enactment of the 21st Century Cures Act in late 2016, FDA approval of RiVax™ has the potential to position the vaccine for a biodefense Priority Review Voucher (PRV), which may be utilized in future programs or sold. PRVs, under similar voucher programs such as with pediatric rare disease drug development, have sold for as much as $350 million.

About the Society of Toxicology Meeting

The Society of Toxicology (SOT) annual meeting is one of the largest annual meetings of toxicologists worldwide and brings together approximately 6500 toxicologists from over 50 countries. This year is the 56^th annual meeting and will be held in Baltimore Maryland. The Society of Toxicology has a mission to “creat[e] a safer and healthier world by advancing the science and increasing the impact of toxicology.” Details regarding the annual meeting can be found at: http://www.toxicology.org/events/am/AM2017/general_information.asp .

About Ricin Toxin

Ricin toxin is a lethal plant-derived toxin and potential biological weapon because of its stability, high potency, and readily extracted from by-products of castor oil production.  Ricin comes in many forms including powder, mist, or pellet. Ricin can also be dissolved in water and other liquids.  The US Centers for Disease Control and Prevention (CDC) estimates the lethal dose in humans is about the size of a grain of salt.  Ricin toxin illness causes tissue necrosis and general organ failure leading to death within several days of exposure.  Ricin is especially toxic when inhaled.  Ricin works by entering cells of the body and preventing the cells from making the proteins it needs.  Without the proteins, cells die, which is eventually harmful to the entire body.

There are currently no effective treatments for ricin poisoning.  The successful development of an effective vaccine against ricin toxin may act as a deterrent against the actual use of ricin as a biological weapon and could be used in rapid deployment scenarios in the event of a biological attack.

About RiVax™

RiVax™ is Soligenix’s proprietary heat stable recombinant subunit vaccine developed to protect against exposure to ricin toxin. With RiVax™, Soligenix is a world leader in the area of ricin toxin vaccine research.

RiVax™ contains a genetically altered version of a Ricin Toxin A (RTA) chain containing two mutations that inactivate the toxicity of the ricin molecule. A Phase 1A clinical trial was conducted with a formulation of RiVax™ that did not contain an adjuvant. This trial revealed dose dependent seroconversion as well as lack of toxicity of the molecule when administered intramuscularly to human volunteers. The adjuvant-free formulation of RiVax™ induced toxin neutralizing antibodies that lasted up to 127 days after the third vaccination in several individuals.

To increase the longevity and magnitude of toxin neutralizing antibodies, RiVax™ was subsequently formulated with an adjuvant of aluminum salts (known colloquially as Alum) for a Phase 1B clinical trial. Alum is an adjuvant that is used in many human vaccines, including most vaccines used in infants. The results of the Phase 1B study indicated that Alum-adjuvanted RiVax™ was safe and well tolerated, and induced greater ricin neutralizing antibody levels in humans than adjuvant-free RiVax™. In preclinical animal studies, the Alum formulation of RiVax™ also induced higher titers and longer lasting antibodies than the adjuvant-free vaccine. Vaccination with the thermostabilized Alum-adjuvanted RiVax™ formulation in a large animal model provided 100% protection (p<0.0001) against acute exposure to aerosolized ricin, the most lethal route of exposure for ricin. The protected animals also had no signs of gross lung damage, a serious and enduring ramification with long-term consequences for survivors of ricin exposure.

Heat stabilization of RiVax™ is achieved with the Company’s proprietary ThermoVax^® technology, designed to eliminate the standard cold chain production, distribution and storage logistics required for most vaccines. The technology utilizes precise lyophilization of protein immunogens with conventional aluminum adjuvants in combination with secondary adjuvants for rapid onset of protective immunity with the fewest number of vaccinations. By employing ThermoVax^® during the final formulation of RiVax™, the vaccine has demonstrated enhanced stability and the ability to withstand temperatures at least as high as 40 degrees Celsius (104 degrees Fahrenheit) for up to one year.

The development of RiVax™ has been sponsored through a series of grants from both the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the FDA, which were granted to Soligenix and to the University of Texas Southwestern (UTSW) where the vaccine protein originated. To date, Soligenix, and Dr. Ellen Vitetta and colleagues at UTSW have collectively received approximately $25 million in grant funding from NIAID for development of RiVax™ and related vaccine technologies. RiVax™ would potentially be added to the Strategic National Stockpile and dispensed in the event of a terrorist attack. RiVax™ has received orphan drug designation from the FDA.

As a new chemical entity, an FDA approved RiVax™ vaccine has the potential to qualify for a biodefense Priority Review Voucher. Approved under the 21st Century Health Cures Act in late 2016, the biodefense PRV is awarded upon approval as a medical countermeasure when the active ingredient(s) have not been otherwise approved for use in any context. PRVs are transferable and can be sold, with sales in recent years varying from between $125 million to $350 million. When redeemed, PRVs entitle the user to an accelerated review period of six months, saving a median of seven months review time as calculated in 2009. However, FDA must be advised 90 days in advance of the use of the PRV and the use of a PRV is associated with an additional user fee ($2.7 million in 2017).

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn’s disease (SGX203) and acute radiation enteritis (SGX201).

Our Vaccines/BioDefense business segment includes active development programs for RiVax™, our ricin toxin vaccine candidate, OrbeShield®, our GI acute radiation syndrome therapeutic candidate and SGX943, our melioidosis therapeutic candidate. The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®.  To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company’s website at www.soligenix.com.

This press release may contain forward-looking statements that reflect Soligenix, Inc.’s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment.  Statements that are not historical facts, such as “anticipates,” “estimates,” “believes,” “hopes,” “intends,” “plans,” “expects,” “goal,” “may,” “suggest,” “will,” “potential,” or similar expressions, are forward-looking statements.  These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements.  Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to timing or success of the clinical trials of RiVax™, that RiVax™ will be approved for the PRV program or the amount for which a PRV for RiVax™ can be sold. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix’s reports on Forms 10-Q and 10-K.  Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

$AUXO Wins $12.5 Million Print as a Service Contract with Prestigious University

Auxilio, Inc. (NYSE MKT: AUXO), a leading provider of complete document workflow solutions and IT security services for the healthcare industry, today announced a five-year, approximately $12.5 million contract with a 1,000-bed prestigious teaching hospital located in the Central United States.

Under the terms of the contract, Auxilio will deliver a next-generation Managed Print Service (MPS) program, otherwise known as Print-as-a-Service (PRaaS), which provides a scalable and customizable service that enables healthcare providers to strategically manage their high-volume print environments by driving operational efficiencies and addressing security vulnerabilities. The service level agreement aims to improve operational efficiency through leveraging Auxilio’s printer break/fix, toner, support, device refresh and consolidation services.

“Our goal is to drive out costs, saving up to 50% over five years for the university medical center. Our priority is streamlining the fragmented print environment and then introducing workflow solutions to transform document processes to digital workflows and implement a security strategy to protect PHI found on devices, the network and printed documents,” said Sean Hughes, EVP of Operations.

“This contract is the latest evidence of the growing demand for our comprehensive, service-oriented programs that deliver deep insights into the document life cycle to reduce print, improve workflow efficiency and enhance security at healthcare organizations,” said Joseph J. Flynn, CEO of Auxilio.

Auxilio’s PRaaS offering provides hospitals the ability to choose the level of service needed. Its flexible PRaaS plans range from toner management and break/fix to an innovative solution that analyzes document workflow and security to optimize and manage the document processes. With the recent acquisition of CynergisTek, an industry leader in health information privacy, compliance and cybersecurity consulting, Auxilio can now offer its healthcare clients integrated document and device security solutions that reduce risk and deliver long-term value.

About Auxilio, Inc.

Auxilio (www.auxilioinc.com) provides complete document workflow solutions and IT security services to healthcare organizations across the United States. Auxilio has helped its clients save more than $80 million since 2004 by providing Print as a Service (PRaaS) vendor neutral solutions which lower costs, improve operational efficiency and enhance security. Auxilio’s intelligent workflow automation suite delivers a customer driven approach transforming printed documents to digital workflows, reducing waste and driving additional savings opportunities. Auxilio serves a national portfolio of nearly 220 hospital campuses and manages over 1.5 billion documents annually from over 90,000 devices supporting over 280,000 caregivers.

CynergisTek (www.CynergisTek.com) is a top-ranked cybersecurity and privacy consulting firm. The company offers solutions to help organizations measure privacy and security programs against regulatory requirements and assists in developing risk management best practices. Since 2004 the company has served as a partner to hundreds in the healthcare industry and is dedicated to supporting and educating the industry by contributing to relevant industry associations. The company has been named in numerous research reports as one of the top firms that provider organizations turn to for privacy and security, and won the 2017 Best in KLAS award for Cyber Security Advisory Services.

For more information about Auxilio, visit http://www.auxilioinc.com.

Forward Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the enhancement of shareholder value the Company’s strategy relating to uplisting to a national exchange, and the Company’s future ability to increase liquidity and attract institutional investors. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from the Company.

Media Contact:
Aria Marketing
Danielle Johns
Account Executive
617-332-9999 x 241
djohns@ariamarketing.com
or
Investor Relations Contact:
MZ North America
Mike Cole
949-259-4988
Mike.cole@mzgroup.us

$WLDN to Participate in 29th Annual ROTH Conference

Willdan Group, Inc. (“Willdan”) (NASDAQ: WLDN), a provider of professional technical and consulting services, today announced that it will participate in the 29^th Annual ROTH Conference in Orange County on Monday, March 13, 2017. During the conference, Willdan will make a presentation and hold a series of meetings with institutional investors. The Willdan Group presentation is scheduled for 3:30 p.m. PT.

A live webcast of the presentation will be available on the company’s website at www.willdan.com under the “Investors: Events and Presentations” section. An archived version will be available in the same location shortly after the conclusion of the presentation.

About Willdan Group, Inc.

Willdan provides professional consulting and technical services to utilities, public agencies and private industry throughout the United States. Willdan’s service offerings span a broad set of complementary disciplines that include energy efficiency and sustainability, engineering and planning, financial and economic consulting, and national preparedness. Willdan provides integrated technical solutions to extend the reach and resources of its clients, and provides all services through its subsidiaries specialized in each segment. For additional information, visit Willdan’s website at www.willdan.com.

$ISTR Assigns BBB & K3 Senior Unsecured & Short-Term Debt Ratings to Investar

Kroll Bond Rating Agency (KBRA) has assigned a senior unsecured debt rating of BBB, subordinated debt rating of BBB-, and short-term debt rating of K3 for Investar Holding Corporation (NASDAQ:ISTR), a bank holding company headquartered in Baton Rouge, Louisiana. In addition, KBRA has assigned senior unsecured debt and deposit ratings of BBB+, a subordinated debt rating of BBB, and short-term debt and deposit ratings of K2 for the subsidiary bank, Investar Bank. The Outlook on all long-term ratings is Stable.

The ratings are supported by Investar Holding Corporation’s solid capital position, strong credit culture and conservative risk appetite, and comprehensive risk management complemented by bench depth across the various areas of risk management. The ratings are constrained by the narrow diversity in revenue streams with significant concentration in spread-derived revenues, comparatively weaker deposit franchise, and below peer earnings metrics, though these are partially offset by a deposit rich acquisitive strategy which is expected to help diversify the deposit base and lower funding costs.

The ratings are based on KBRA’s Global Bank and Bank Holding Company Rating Methodology, published on February 19, 2016.

Please click here to view the report.

About Kroll Bond Rating Agency

KBRA is registered with the U.S. Securities and Exchange Commission as a Nationally Recognized Statistical Rating Organization (NRSRO). In addition, KBRA is recognized by the National Association of Insurance Commissioners (NAIC) as a Credit Rating Provider (CRP).

Analytical:
Kroll Bond Rating Agency
M Scott Durant, 301-969-3248
Associate Director
sdurant@kbra.com
or
Joseph Scott, 646-731-2438
Managing Director
jscott@kbra.com
or
Christopher Whalen, 646-731-2366
Senior Managing Director
cwhalen@kbra.com
or
Follow us on Twitter!
@KrollBondRating

$SITO Mobile Launches SITO LABS — a Data as a Service (DaaS) Mobile Marketing Solution

SITO Mobile will offer its extensive location-based mobile data to marketers to help them better understand their customers and prospects

Screenvision Media is first to sign on as a LABS client

JERSEY CITY, N.J., March 09, 2017  — Today, SITO Mobile Ltd. (NASDAQ:SITO), a leading mobile engagement platform, has introduced SITO LABS (Location Audience Behavioral Sciences), a Data as a Service (DaaS) mobile marketing solution to help marketers analyze and target consumers. Through SITO LABS, marketers will use SITO Mobile’s location-based data to access enhanced behavioral data and analytics about custom audiences and locations.

Screenvision Media, a national leader in cinema advertising, will be SITO LABS’ first customer.

In addition to actual location data, the dynamics of the mobile media ecosystem – hundreds of millions of consumers continuously interacting with mobile devices as they move throughout their day – provides the opportunity for unique two-way information sharing, so insights into consumers’ movements and behaviors can also be analyzed and addressed.  This dynamic data flow provides constantly updated and ever-changing information about consumer preferences and behavior.

The launch of SITO LABS is a first step in recognizing and monetizing the powerful potential of this data asset and is generating additional revenue beyond SITO’s primary media placement and attribution/measurement business. SITO LABS further leverages the company’s location-based dataset by providing advertisers with additional information about the efficacy of their targeting and conversion efforts.

“SITO Mobile’s launch of SITO LABS represents our initial steps toward productizing and monetizing our owned-and-operated data asset and is part of our broader efforts to leverage the complementary value of our data management platform (DMP) and its powerful location-based mobile data,” said Jon Lowen, SITO Mobile’s EVP of Operations and Product Development. “Our large and growing mobile data DMP provides unique and dynamic insights into mobile consumers’ location-based behavior.  Mobile location-based consumer data extends the insights available to marketers far beyond their traditional CRM tools.”

Lowen continued, “SITO LABS, in combination with our capability to deliver media and report on attribution in real-time, offers our clients an end-to-end marketing and advertising solution that provides increased performance and one platform on which to plan, execute and measure media spend.”

“We’ve made a strong commitment to leveraging mobile and other technologies to elevate our moviegoer insights and, in turn, deliver greater value for our clients. We have developed a solid alliance with SITO Mobile over the past few years, and are excited for that relationship to evolve as we continue tapping into the rich data and insights that will be gleaned from SITO LABS,” said John McCauley, Chief Strategic Development Officer, Screenvision Media. “As a company, we are always looking for opportunities to strengthen our audience targeting capabilities for brands. Gathering additional behavioral data points about who comes to the movies each week, and what they do once they leave, is invaluable in this effort.”

SITO Mobile’s owned-and-operated marketing platform provides access to more than 98% of U.S. and Canadian mobile consumers via more than 200,000 of the most popular apps. Additionally, it feeds approximately 4.5 trillion monthly data points through its machine-learning algorithms – thus continuously improving its location-based audience targeting and real time delivery optimization.

About SITO Mobile Ltd.

SITO Mobile provides a mobile engagement platform that enables brands to increase awareness, loyalty, and ultimately sales. For more information, visit www.sitomobile.com.

About Screenvision Media

Headquartered in New York, N.Y., Screenvision Media is a national leader in cinema advertising, offering on-screen advertising, in-lobby promotions and integrated marketing programs to national, regional and local advertisers and providing comprehensive cinema advertising representation services to top tier theatrical exhibitors presenting the highest quality moviegoing experience. The Screenvision Media cinema advertising network is comprised of over 14,500 screens in 2,300+ theater locations across all 50 states and 94% of DMAs nationwide; delivering through more than 150 theatrical circuits, including 6 of the top 10 exhibitor companies. For more information: http://screenvisionmedia.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, sales growth, our reliance on brand owners and wireless carriers, the possible need for additional capital as well as other risks identified in our filings with the SEC. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

RELATED LINKS
http://www.sitomobile.com

Contacts:
Investor Relations:
Joseph Wilkinson
SVP Investor Relations
Joseph.Wilkinson@sitomobile.com

Media Relations:
Alexandra Levy
Silicon Alley Media
alex@siliconalley-media.com